Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
301.35(c) 300.15(c) 298.5(c) 301.5(c) 302.3 Last
2 204 085 1 928 144 2 571 936 3 554 065 121 595 Volume
-0.61% -0.40% -0.55% +1.01% +0.27% Change
More quotes
Financials (DKK)
Sales 2018 111 B
EBIT 2018 46 610 M
Net income 2018 39 077 M
Finance 2018 16 422 M
Yield 2018 2,66%
Sales 2019 116 B
EBIT 2019 48 977 M
Net income 2019 39 450 M
Finance 2019 17 442 M
Yield 2019 2,77%
P/E ratio 2018 18,74
P/E ratio 2019 18,19
EV / Sales2018 5,04x
EV / Sales2019 4,80x
Capitalization 577 B
More Financials
Company
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals.The Diabetes & Obesity Care segment covers products for... 
Sector
Pharmaceuticals
Calendar
09/25Presentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
09/21NOVO NORDISK A/S : announces plans to transform its approach to Research and Dev..
AQ
09/21NOVO NORDISK A/S : Ontario becomes first province to provide public funding of T..
AQ
09/21NOVO NORDISK A/S : Oral Semaglutide Demonstrates Benefits for Patients With Type..
AQ
09/20NOVO NORDISK A/S : - Oral semaglutide demonstrates greater reductions in HbA1c a..
GL
09/20NOVO NORDISK A/S : Say hello to Sophia, Novo Nordisk`s new online chatbot, avail..
AQ
09/19PFIZER : Glaxo, Novo, Novartis plants unfazed by hurricane, resume production; M..
AQ
09/19NOVO NORDISK A/S : 400 jobs to go as Novo Nordisk overhauls R&D operations
AQ
09/19DANSKE BANK : issues structured notes linked to Novo Nordisk A/S
AQ
09/18NOVO NORDISK A/S : opens Hemophilia Treatment Center worth LE2m
AQ
09/18NOVO NORDISK A/S : announces plans to transform its approach to Research & Devel..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:30aASTRAZENECA : Mixed Results from Farxiga Trial
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on NOVO NORDISK A/S 
NOVO NORDISK A/S - 08/24
The technical configuration is positive
BUY
NOVO NORDISK A/S - 06/14
Comeback of a rising trend ?
BUY
More Strategies
Latest Tweets
09/23Brokerages Expect Novo Nordisk A/S $NVO to Announce $0.61 EPS  
09/23Comparing Innate Pharma $IPHYF and Adamas Pharmaceuticals $ADMS  
09/22Novo Nordisk A/S $NVO vs. Collegium Pharmaceutical $COLL Financial Contrast  
09/21Novo Nordisk $NVO buyer of 2,000 October $49 calls $0.40 to $0.45 
09/21$NVO Novo nordisk should rally and take out all time highs in 2019-2020 , so .. 
More tweets
Qtime:76
News from SeekingAlpha
09/20Novo's oral semaglutide successful in late-stage T2D study in Japan; shares u.. 
09/19My Quarterly Global Portfolio Update 
09/18Zealand Pharma's dasiglucagon successful in late-stage study in severe hypogl.. 
09/18Novo Nordisk lays off 400 staff in R&D unit 
09/17House nixes drug prices in TV ads 
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 326  DKK
Spread / Average Target 8,0%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-9.87%89 924
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092